Add this result to my export selection Information for Healthcare Professionals on COVID-19 Vaccine AstraZeneca (updated) Source: Medicines and Healthcare products Regulatory Agency - MHRA (Remove filter) Published by Medicines and Healthcare products Regulatory Agency, 07 January 2021 A new version of this vaccine information for UK healthcare professionals includes (in Section 6.6) allowing for an additional dose to be taken if there is sufficient liquid left for a further full... Read Summary Type: Medicines Current Awareness (Remove filter) Type: Guidance (Add filter)
Add this result to my export selection Oxford University/AstraZeneca vaccine authorised by MHRA Source: Medicines and Healthcare products Regulatory Agency - MHRA (Remove filter) Published by Medicines and Healthcare products Regulatory Agency, 30 December 2020 The JCVI has subsequently recommended that as many people on the priority list as possible should be offered a first vaccine dose as the initial priority (as opposed to prioritising completing the 2... Read Summary SPS comment Type: Medicines Current Awareness (Remove filter) Type: Guidance (Add filter)
Add this result to my export selection COVID-19 Vaccine Moderna authorised in the UK for temporary supply Source: Medicines and Healthcare products Regulatory Agency - MHRA (Remove filter) Published by Medicines and Healthcare products Regulatory Agency, 08 January 2021 This is the third Covid-19 vaccine (the second mRNA vaccine) to have been given regulatory approval for supply by the MHRA. It is approved for use in people aged 18 years and requires two doses. Read Summary SPS comment Type: Medicines Current Awareness (Remove filter) Type: Guidance (Add filter)
Add this result to my export selection Interim Position Statement: Interleukin-6 inhibitors (tocilizumab or sarilumab) for patients admitted to ICU with COVID-19 pneumonia (adults) Source: Medicines and Healthcare products Regulatory Agency - MHRA (Remove filter) Published by Medicines and Healthcare products Regulatory Agency, 08 January 2021 The REMAP-CAP platform trial has reported survival and time to recovery benefits for tocilizumab or sarilumab. Clinicians should consider prescribing IV tocilizumab (sarilumab an alternative if... Read Summary SPS comment Type: Medicines Current Awareness (Remove filter) Type: Guidance (Add filter)
Add this result to my export selection Use of medicines in pregnancy and breastfeeding Source: Medicines and Healthcare products Regulatory Agency - MHRA (Remove filter) Published by Medicines and Healthcare products Regulatory Agency, 11 January 2021 This guidance signposts patients, healthcare professionals and developers of new medicines to advice and resources on medicines in pregnancy and breastfeeding and is supported by Safer Medicines in... Read Summary SPS comment Type: Medicines Current Awareness (Remove filter) Type: Guidance (Add filter)
Add this result to my export selection Covid-19 Therapeutic Alert: Colchicine in the Management of COVID-19 (SARS-CoV 2) Positive Patients - Trial Use Only Source: Medicines and Healthcare products Regulatory Agency - MHRA (Remove filter) Published by Medicines and Healthcare products Regulatory Agency, 12 February 2021 Colchicine should NOT be used in the management of COVID-19 positive patients other than in the context of a trial, or unless there is an additional licensed indication for its use. Although early... Read Summary SPS comment Type: Medicines Current Awareness (Remove filter) Type: Guidance (Add filter)
Add this result to my export selection National Patient Safety Alert: Deterioration due to rapid offload of pleural effusion fluid from chest drains Source: Medicines and Healthcare products Regulatory Agency - MHRA (Remove filter) Published by Medicines and Healthcare products Regulatory Agency, 01 December 2020 Alert warns that if large volumes of pleural fluid are drained too quickly from chest drains, patients can rapidly deteriorate from the potentially life-threatening complication of re-expansion... Read Summary SPS comment Type: Safety Alerts (Add filter) Type: Medicines Current Awareness (Remove filter)
Add this result to my export selection Confirmation of guidance to vaccination centres on managing allergic reactions following COVID-19 vaccination with the Pfizer/BioNTech vaccine Source: Medicines and Healthcare products Regulatory Agency - MHRA (Remove filter) Published by Medicines and Healthcare products Regulatory Agency, 09 December 2020 MHRA has advised that any person with a history of anaphylaxis to a vaccine, medicine or food should not receive the Pfizer/BioNTech vaccine; and a second dose should not be given to anyone who has... Read Summary SPS comment Type: Safety Alerts (Add filter) Type: Medicines Current Awareness (Remove filter)
Add this result to my export selection SSRI/SNRI antidepressant medicines: small increased risk of postpartum haemorrhage when used in the month before delivery Source: Medicines and Healthcare products Regulatory Agency - MHRA (Remove filter) Published by Medicines and Healthcare products Regulatory Agency, 07 January 2021 Data from observational studies suggest use of SSRI/SNRI antidepressants during month before delivery may result in small increased risk of postpartum haemorrhage. Prescribers should consider this... Read Summary Type: Safety Alerts (Add filter) Type: Medicines Current Awareness (Remove filter)
Add this result to my export selection Erythromycin: caution required due to cardiac risks (QT interval prolongation); drug interaction with rivaroxaban Source: Medicines and Healthcare products Regulatory Agency - MHRA (Remove filter) Published by Medicines and Healthcare products Regulatory Agency, 17 December 2020 Erythromycin should not be given to patients with a history of QT interval prolongation or ventricular cardiac arrhythmia. A potential drug interaction between rivaroxaban and erythromycin resulting... Read Summary SPS comment Type: Safety Alerts (Add filter) Type: Medicines Current Awareness (Remove filter)